MedPath

Janssen-Cilag International NV

🇧🇪Belgium
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

2.0k

Active:1946
Completed:80

Trial Phases

5 Phases

Phase 1:1554
Phase 2:20
Phase 3:42
+2 more phases

Drug Approvals

263

CIMA_AEMPS:119
NMPA:58
EMA:45
+1 more agencies

Drug Approvals

Guselkumab Injection (Intravenous Infusion)

Product Name
特诺雅达
Approval Number
国药准字SJ20250006
Approval Date
Feb 20, 2025
NMPA

Amivantamab Injection

Product Name
锐珂
Approval Number
国药准字SJ20250005
Approval Date
Feb 8, 2025
NMPA

Talquetamab Injection

Product Name
拓立珂
Approval Number
国药准字SJ20250004
Approval Date
Feb 8, 2025
NMPA

Talquetamab Injection

Product Name
拓立珂
Approval Number
国药准字SJ20250003
Approval Date
Feb 8, 2025
NMPA

Ustekinumab Injection(Intravenous Infusion)

Product Name
喜达诺
Approval Number
国药准字SJ20200005
Approval Date
Jan 15, 2025
NMPA

Canagliflozin Tablets

Product Name
怡可安
Approval Number
国药准字HJ20170374
Approval Date
Dec 31, 2024
NMPA

Canagliflozin Tablets

Product Name
怡可安
Approval Number
国药准字HJ20170375
Approval Date
Dec 31, 2024
NMPA

Niraparib Tosylate and Abiraterone Acetate Tablets

Product Name
尼拉帕利阿比特龙片
Approval Number
国药准字HJ20240110
Approval Date
Oct 16, 2024
NMPA

Niraparib Tosylate and Abiraterone Acetate Tablets

Product Name
尼拉帕利阿比特龙片
Approval Number
国药准字HJ20240111
Approval Date
Oct 16, 2024
NMPA

Abiraterone Acetate Tablets

Product Name
泽珂
Approval Number
国药准字HJ20150264
Approval Date
Oct 8, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

Clinical Trials

Distribution across different clinical trial phases (1622 trials with phase data)• Click on a phase to view related trials

Phase 1
1554 (95.8%)
Phase 3
42 (2.6%)
Phase 2
20 (1.2%)
Phase 4
5 (0.3%)
Not Applicable
1 (0.1%)

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

First Posted Date
2021-06-25
Last Posted Date
2025-04-27
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
93
Registration Number
NCT04940039
Locations
🇷🇼

University Teaching Hospital of Butare(CHUB), Butare, Rwanda

🇷🇼

Kibuye Referral Hospital, Kibuye, Rwanda

🇷🇼

CARAES Ndera Neuro-Psychiatric Hospital, Kigali, Rwanda

and more 2 locations

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

First Posted Date
2020-04-08
Last Posted Date
2025-04-29
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
676
Registration Number
NCT04338321
Locations
🇦🇷

FunDaMos, Ciudad Autonoma de Buenos Aires, Argentina

🇦🇷

Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales, Ciudad Autónoma De Buenos Aires, Argentina

🇦🇷

CEN Consultorios Especializados en Neurociencias, Cordoba, Argentina

and more 165 locations

A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment

Phase 1
Terminated
Conditions
Kidney Failure, Chronic
Interventions
First Posted Date
2019-05-13
Last Posted Date
2025-02-03
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
29
Registration Number
NCT03947814
Locations
🇩🇪

CRS Clinical Research Services Kiel GmbH, Kiel, Germany

🇩🇪

APEX GmbH, Munchen, Germany

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

Phase 3
Completed
Conditions
Psoriasis
Interventions
Drug: Placebo Injection
First Posted Date
2019-01-28
Last Posted Date
2025-04-27
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
880
Registration Number
NCT03818035
Locations
🇩🇪

Universitatsklinikum Dusseldorf, Düsseldorf, Germany

🇫🇷

Hopital Prive d'Antony, Antony, France

🇫🇷

Centre Hospitalier d'Auxerre, Auxerre, France

and more 81 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 14
  • Next

News

EC Approves Amivantamab Plus Lazertinib for First-Line EGFR-Mutated NSCLC

• The European Commission has approved amivantamab plus lazertinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). • The approval is based on the Phase 3 MARIPOSA trial, which showed superior progression-free survival compared to osimertinib. • The combination therapy reduced the risk of disease progression or death by 30% compared to osimertinib monotherapy. • Common adverse events were manageable and primarily Grade 1 or 2, supporting the combination's safety profile.

CHMP Recommends Subcutaneous Amivantamab for EGFR-Mutated NSCLC Treatment

The CHMP has recommended subcutaneous amivantamab with lazertinib for first-line treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

RYBREVANT Plus Chemotherapy Shows Positive Survival Trend in EGFR-Mutated Lung Cancer

Updated results from the Phase 3 MARIPOSA-2 study show RYBREVANT plus chemotherapy demonstrates a favorable trend toward improved overall survival.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.